Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9178984 | 1.00 | ASGR1 (0.41) | ASGR1HSD11B1SSTR4NFKB1NFKB2 | |
| SCHEMBL31633856 | 1.00 | ASGR1 (0.41) | ASGR1HSD11B1SSTR4NFKB1NFKB2 | |
| SCHEMBL5438279 | 0.83 | ASGR1 (0.39) | ASGR1HSD11B1 | |
| SCHEMBL785468 | 0.81 | HSD11B1 (0.41) | ASGR1HSD11B1NFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL2401902 | 0.80 | HSD11B1 (0.40) | ASGR1HSD11B1NFKB1NFKB2RELA | |
| SCHEMBL22236163 | 0.79 | CHRNB2 (0.37) | SSTR4 | |
| SCHEMBL14428327 | 0.79 | HSD11B1 (0.42) | ASGR1HSD11B1NFKB1NFKB2RELA | |
| SCHEMBL2092023 | 0.78 | HSD11B1 (0.35) | ASGR1HSD11B1SSTR4 | |
| SCHEMBL25282846 | 0.77 | ASGR1 (0.37) | ASGR1HSD11B1 | |
| SCHEMBL22138095 | 0.77 | ASGR1 (0.37) | ASGR1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
| EP-1828174-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006054162-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | ASGR1 253/4885HSD11B1 1683/4885SSTR4 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.